Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

ClinicalTrials.gov ID: NCT04459715

Public ClinicalTrials.gov record NCT04459715. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

Study identification

NCT ID
NCT04459715
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Enrollment
730 participants

Conditions and interventions

Interventions

  • Xevinapant (Debio 1143) Drug
  • Cisplatin Drug
  • Intensity Modulation Radiation Therapy (IMRT) Radiation
  • Placebo Drug

Drug · Radiation

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 6, 2020
Primary completion
Sep 17, 2024
Completion
Sep 17, 2024
Last update posted
Oct 7, 2025

2020 – 2024

United States locations

U.S. sites
44
U.S. states
24
U.S. cities
36
Facility City State ZIP Site status
The University of Alabama at Birmingham - Hazelrig-Salter Radiation Oncology Center (HSROC) Birmingham Alabama 35233
Banner MD Anderson Cancer Center Gilbert Arizona 85234
University of Arizona Cancer Center Tucson Arizona 85724
UC San Diego Moores Cancer Center La Jolla California 92093
Regents of the University of California San Francisco California 94158
UCSF San Francisco California 94158
The Oncology Institute of Hope & Innovation Whittier California 90603
University of Colorado at Denver and Health Sciences Center Aurora Colorado 80045
Yale Cancer Center New Haven Connecticut 06519
Lombardi Comprehensive Cancer Center, Georgetown University Medical Center Washington D.C. District of Columbia 20007
Moffitt Cancer Center Tampa Florida 33612
ASCLEPES Research Centers Weeki Wachee Florida 34607
Columbus Regional Research Institute Columbus Georgia 31904
IACT Health, John B. Amos Cancer Center Columbus Georgia 31904
Inventa Center for Cancer Research At Fort Wayne Medical Oncology and Hematology Fort Wayne Indiana 46804
Ashland-Bellefonte Cancer Center Ashland Kentucky 41101
Norton Cancer Institute, Louisville, Kentucky, Brownsboro Hospital Campus Louisville Kentucky 40241
Massachusetts General Hospital Boston Massachusetts 02114-2696
Beth Israel Deaconess (BI Lahey)/Harvard Cancer Center Boston Massachusetts 02215
Dana-Farber Cancer Institute Boston Massachusetts 02215
University South Hospital Ann Arbor Michigan 48109-9001
Henry Ford Health System Detroit Michigan 48202
Karmanos Cancer institute Detroit Michigan 48302
University of Missouri - Ellis Fischel Cancer Center Columbia Missouri 65212
MidAmerica Cancer Care Kansas City Missouri 64114
Washington University School of Medicine St Louis Missouri 63110
Comprehensive Cancer Center of Nevada (Southern Hills) (USA) Las Vegas Nevada 89148
Comprehensive Cancer Centers of Nevada Las Vegas Nevada 89169
NYU Langone Hospital-Long Island Oncology Mineola New York 11501
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health New York New York 10016
NYU Grossman School of Medicine New York New York 10016
Wake Forest University School of Medicine Winston-Salem North Carolina 27157
University of Cincinnati Medical Center Cincinnati Ohio 45267
University Hospital Cleveland Medical Center Cleveland Ohio 44106
Cleveland Clinic Cleveland Ohio 44195
Ohio State University Columbus Ohio 43210
University of Oklahoma Health Sciences Center- Stephenson Cancer Center Oklahoma City Oklahoma 73104
Providence Portland Medical Center Portland Oregon 97213
Gettysburg Cancer Center Gettysburg Pennsylvania 17325
Fox Chase Cancer Center Philadelphia Pennsylvania 19111
Medical University of South Carolina- Hollings Cancer Center Charleston South Carolina 29425
MD Anderson Houston Texas 77030
IHO Corporation/Utah Cancer Specialists Salt Lake City Utah 84106
University of Virginia Medical Center Charlottesville Virginia 22908

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 244 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04459715, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 7, 2025 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04459715 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →